DE60326153D1 - Verfahren zur diagnose von morbus alzheimer - Google Patents

Verfahren zur diagnose von morbus alzheimer

Info

Publication number
DE60326153D1
DE60326153D1 DE60326153T DE60326153T DE60326153D1 DE 60326153 D1 DE60326153 D1 DE 60326153D1 DE 60326153 T DE60326153 T DE 60326153T DE 60326153 T DE60326153 T DE 60326153T DE 60326153 D1 DE60326153 D1 DE 60326153D1
Authority
DE
Germany
Prior art keywords
diagnosis
subject
methods
present
morbus alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60326153T
Other languages
English (en)
Inventor
Yadong Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J David Gladstone Institutes
Original Assignee
J David Gladstone Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J David Gladstone Institutes filed Critical J David Gladstone Institutes
Application granted granted Critical
Publication of DE60326153D1 publication Critical patent/DE60326153D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
DE60326153T 2002-07-30 2003-07-24 Verfahren zur diagnose von morbus alzheimer Expired - Lifetime DE60326153D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40001602P 2002-07-30 2002-07-30
PCT/US2003/023093 WO2004011943A1 (en) 2002-07-30 2003-07-24 Method of diagnosing alzheimer's disease

Publications (1)

Publication Number Publication Date
DE60326153D1 true DE60326153D1 (de) 2009-03-26

Family

ID=31188657

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60326153T Expired - Lifetime DE60326153D1 (de) 2002-07-30 2003-07-24 Verfahren zur diagnose von morbus alzheimer

Country Status (6)

Country Link
US (1) US7682795B2 (de)
EP (1) EP1543331B1 (de)
AT (1) ATE422671T1 (de)
AU (1) AU2003259222A1 (de)
DE (1) DE60326153D1 (de)
WO (1) WO2004011943A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005051998A2 (en) * 2003-11-28 2005-06-09 Astrazeneca Ab Antibodies binding to a c-terminal fragment of apolipoprotein e
US7612179B2 (en) * 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20090136456A1 (en) * 2006-12-22 2009-05-28 Yadong Huang Methods of treating neurodegenerative disorders
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
WO2009062152A1 (en) * 2007-11-09 2009-05-14 Washington University In St. Louis Methods for measuring the metabolism of cns derived biomolecules in vivo
US9102717B2 (en) * 2010-03-01 2015-08-11 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof
CN102933601B (zh) 2010-04-15 2016-06-08 Abbvie公司 β淀粉样蛋白结合蛋白
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9488666B2 (en) 2010-08-24 2016-11-08 Helena Laboratories Corporation Assay for determination of levels of lipoprotein particles in bodily fluids
US8741298B2 (en) 2011-02-07 2014-06-03 Neotope Biosciences Limited APOE immunotherapy
EP3760235A1 (de) 2014-09-30 2021-01-06 Washington University Kinetische tau-messungen
AU2016210835B2 (en) * 2015-01-29 2021-01-21 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US6287793B1 (en) * 1988-08-19 2001-09-11 Elan Pharmaceuticals, Inc. Diagnostic methods for alzheimer's disease
AU2414092A (en) * 1991-08-01 1993-03-02 Paul H. Voorheis Diagnostic method for alzheimer's disease
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
WO1994009371A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
DE69333461T2 (de) * 1992-10-13 2005-03-24 Duke University VERFAHREN ZUM nachweis der Alzheimer Krankheit
US6300085B1 (en) * 1993-05-03 2001-10-09 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic method for Alzheimer's disease
US5849600A (en) * 1993-11-10 1998-12-15 The Mclean Hospital Corporation Diagnostic assays for Alzheimer's disease
FR2716894B1 (fr) * 1994-03-07 1996-05-24 Pasteur Institut Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic.
US5976798A (en) * 1994-03-30 1999-11-02 Mitokor Methods for detecting mitochondrial mutations diagnostic for Alzheimer's disease and methods for determining heteroplasmy of mitochondrial nucleic acid
US5972634A (en) * 1994-10-19 1999-10-26 The General Hospital Corporation Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities
US5817789A (en) * 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5976817A (en) * 1996-10-31 1999-11-02 Trustees Of Boston University Diagnostic method for detecting Alzheimer's disease in living patients
AU3068899A (en) * 1998-03-05 1999-09-20 Board Of Regents, The University Of Texas System Diagnostic assay for late-onset alzheimer's disease
CA2426030C (en) * 2000-11-03 2013-12-31 The J. David Gladstone Institutes Methods of treating disorders related to apoe
US6766817B2 (en) * 2001-07-25 2004-07-27 Tubarc Technologies, Llc Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action

Also Published As

Publication number Publication date
EP1543331A1 (de) 2005-06-22
EP1543331B1 (de) 2009-02-11
WO2004011943A1 (en) 2004-02-05
US7682795B2 (en) 2010-03-23
US20040157267A1 (en) 2004-08-12
AU2003259222A1 (en) 2004-02-16
ATE422671T1 (de) 2009-02-15
EP1543331A4 (de) 2006-08-02

Similar Documents

Publication Publication Date Title
DE60326153D1 (de) Verfahren zur diagnose von morbus alzheimer
ATE535535T1 (de) Methoden für die diagnose von demenz und anderen neurologischen erkrankungen
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
ATE283485T1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
ATE412003T1 (de) Verfahren zur diagnose der alzheimer erkrankung auf der basis eines gen transkriptionsmusters
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
DE60332538D1 (de) Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen
DE502006008028D1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
ATE406579T1 (de) Verfahren zur diagnose von tumoren
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
ATE480641T1 (de) Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes
DE60333195D1 (de) Verfahren zur diagnose des myokardinfarktrisikos
ATE465408T1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
DE602006015221D1 (de) Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression
DE50007635D1 (de) Verfahren zur diagnose von sjögren-syndrom
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
ATE509271T1 (de) Verfahren zur diagnose von myasthenia gravis
WO2003104812A3 (en) DIAGNOSIS ASSAY FOR ALZHEIMER'S DISEASE BASED ON THE DETERMINATION OF THE HA DOLLAR G (B) 42 RATE: HA DOLLAR G (B) 40
ATA19972000A (de) Pibf für die diagnose von tumoren
ATE302416T1 (de) Auf holo-transcobalamin ii beruhendes diagnostisches verfahren für alzheimer-krankheit
ATE397090T1 (de) Verfahren und verbindungen zur diagnose von entzündlichen erkrankungen und identifizierung von pharmakologischen mitteln zur behandlung von entzündlichen erkrankungen
ATE441859T1 (de) Verfahren zur diagnose der immunität wiederkehrenden spontanen schwangerschaftsabbruchs sowie verfahren zur behandlung und überwachung
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition